Bristol-Myers Squibb Company · NYSE:BMY
Bristol-Myers Squibb — Merger or Acquisition (October 2023)
15 slides from Bristol-Myers Squibb's merger presentation, Oct 8, 2023
Slide 1: Bristol Myers Squibb Strengthens & Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics
Bristol Myers Squibb Strengthens & Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics October 8, 2023 Not for Product Promotional Use
Slide 2: Cautionary Statements
Cautionary Statements Additional Information and Where to Find it In connection with the proposed acquisition of Mirati by Bristol Myers Squibb, Mirati intends to file a preliminary and definitive proxy statement. The definitive proxy statement and proxy card will be delivered to the stockholders of
Slide 3: Cautionary Statements (Cont.)
Cautionary Statements (Cont.) Cautionary Statement Regarding Forward-Looking Statements This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding,
Slide 4: Cautionary Statements (Cont.)
Cautionary Statements (Cont.) Use of Non-GAAP Financial Information and Financial Guidance In discussing financial guidance, Bristol Myers Squibb refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The non-GAAP financial measures are pro
Slide 5: Mirati Therapeutics: Strong Strategic Fit
Mirati Therapeutics: Strong Strategic Fit Compelling Assets • KRAZATI (adagrasib): best-in-class KRASG12C inhibitor with opportunity across multiple tumor types ‒ Strong launch in 2L+ NSCLC; >40% share of new patients ‒ 1L NSCLC Phase 3 initiation by YE 2023; 3L+ CRC filing by YE 2023; 2L CRC data i
Slide 6: Transaction Overview
Transaction Overview Agreement to Differentiated KRAZATI: Creates value acquire Mirati for: oncology portfolio: Best-in-class KRASG12C for BMS inhibitor $58.00 KRAZATI IRR exceeds Mirati cost of capital per share in cash (KRASG12C Inhibitor) Approved in 2L KRASG12C NSCLC Maintain strong financial fl
Slide 7: Mirati: Innovative Targeted Oncology Company
Mirati: Innovative Targeted Oncology Company OVERVIEW OF MIRATI PIPELINE Compound Development Development Phase • FDA approved in 2L KRASG12C Indication / MoA Approach Phase 1/1b Phase 2 Phase 3 mutated NSCLC Monotherapy1 2L NSCLC • Best-in-class KRASG12C profile Adagrasib + in 1L NSCLC and CRC NSCL
Slide 8: Strong Commercial Fit with Oncology Portfolio
Strong Commercial Fit with Oncology Portfolio KRAZATI Enhances Oncology Franchise Extending in IO Diversifying beyond IO Repotrectinib (PDUFA: 11/27/23) Diversifies BMS BMS leading oncology commercial Leverage BMS global oncology portfolio infrastructure can accelerate commercial footprint to ensure
Slide 9: KRAZATI (adagrasib)
KRAZATI (adagrasib) Differentiated KRASG12C Inhibitor with Broad Development Program to Maximize Potential for Patients 2L+ Lung Cancer 1L Lung Cancer Colorectal Cancer CNS Penetrant Monotherapy Combination with Pembro Monotherapy / or Pembro and Combination with Chemotherapy Cetuxibmab Combinabilit
Slide 10: KRAZATI (adagrasib): Opportunity to expand to 1L NSCLC
KRAZATI (adagrasib) Opportunity to expand to 1L NSCLC 1L NSCLC with TPS ≥ 50% 1L NSCLC with TPS < 50% Demonstrated early efficacy in combination with pembrolizumab Strategy to raise the standard of care • 63% ORR1,2,3 (N=56) through combination with chemotherapy and pembrolizumab • Substantially exc
Slide 11: MRTX1719
MRTX1719 Potential first-in-class and best-in-class potent selective PRMT5/MTA inhibitor Significant unmet need and commercial opportunity Encouraging Early Clinical Data: MTAP deletions occur in ~10% of cancer, representing >250,000 annual Phase 1 Dose Escalation1 incidents across lines of therapie
Slide 12: Early clinical pipeline features a KRAS and KRAS enabling program
Early clinical pipeline features a KRAS and KRAS enabling program MRTX1133 MRTX0902 Selectively and reversibly binds to and inhibits Potent and selective small molecule SOS1 inhibitor KRASG12D in both active and inactive states with that disrupts the KRAS SOS1 interaction shifting KRAS Phase 1 to it
Slide 13: Mirati Therapeutics: Strong Strategic Fit
Mirati Therapeutics: Strong Strategic Fit Compelling Assets • KRAZATI (adagrasib): best-in-class KRASG12C inhibitor with opportunity across multiple tumor types ‒ Strong launch in 2L+ NSCLC; >40% share of new patients ‒ 1L NSCLC Phase 3 initiation by YE 2023; 3L+ CRC filing by YE 2023; 2L CRC data i
Slide 14: Appendix
Appendix Not for Product Promotional Use 14
Slide 15: Establishing Leadership Across Key Oncogenic Mutations
Establishing Leadership Across Key Oncogenic Mutations1 KRAS Prevalence in Tumors With High Unmet Needs Prevalence of Oncogenic Mutations in Metastatic NSCLC 2 (metastatic tumors) KRASG12C MT occur in 2% KRAS G12A 14% ~14% of NSCLC, NSCLC 4% KRASG12C comparable to the KRAS G12C 14% prevalence of EGF
Bristol Myers Squibb — Merger or Acquisition (October 2023) on 6ix